XXB750 / Novartis - LARVOL DELTA

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure (clinicaltrials.gov) - P2 | N=136 | Terminated | Sponsor: Novartis Pharmaceuticals | Trial completion date: Dec 2025 ➔ Nov 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Oct 2025 ➔ Nov 2024; Sponsor Decision

Trial completion date • Trial primary completion date • Trial termination • Cardiovascular • Congestive Heart Failure • Heart Failure

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. (clinicaltrials.gov) - P2 | N=194 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure (clinicaltrials.gov) - P2 | N=136 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=720 ➔ 136

Enrollment change • Enrollment closed • Cardiovascular • Congestive Heart Failure • Heart Failure

A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of XXB750 in heart failure patients with reduced or mildly reduced ejection fraction (ESC 2024) - No abstract available

Clinical • Late-breaking abstract • Cardiovascular • Congestive Heart Failure • Heart Failure

Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants (clinicaltrials.gov) - P1 | N=77 | Completed | Sponsor: Novartis Pharmaceuticals

New P1 trial

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. (clinicaltrials.gov) - P2 | N=191 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Hypertension

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF) (clinicaltrials.gov) - P1 | N=27 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Congestive Heart Failure • Heart Failure

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. (clinicaltrials.gov) - P2 | N=170 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Mar 2024 ➔ Sep 2024 | Trial primary completion date: Feb 2024 ➔ Sep 2024

Trial completion date • Trial primary completion date • Cardiovascular • Hypertension

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure (clinicaltrials.gov) - P2 | N=720 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure (clinicaltrials.gov) - P2 | N=720 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Oct 2025 ➔ Jan 2026 | Trial primary completion date: Aug 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF) (clinicaltrials.gov) - P1 | N=27 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Congestive Heart Failure • Heart Failure

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure (clinicaltrials.gov) - P2 | N=720 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

Safety and Blood Pressure Lowering Effects of a Novel and Long-Acting Natriuretic Peptide Receptor 1 Agonist in Healthy Participants: A First-in-Human Clinical Study (AHA 2023) - "We reported for the first time that a novel long acting NPR1 agonist, XXB750, significantly increases plasma cGMP and reduces BP in a dose-dependent manner in humans. XXB750 has the potential for future development as a novel therapy for cardiovascular diseases."

Clinical • P1 data • Cardiovascular

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF) (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Aug 2023 ➔ Apr 2024 | Trial primary completion date: Aug 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF) (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jun 2024 ➔ Aug 2023 | Trial primary completion date: Jun 2024 ➔ Aug 2023

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF) (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Sep 2023 ➔ Jun 2024 | Trial primary completion date: Sep 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced Ejection Fraction (HFrEF) (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jun 2023 ➔ Sep 2023 | Trial primary completion date: Jun 2023 ➔ Sep 2023

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. (clinicaltrials.gov) - P2 | N=170 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting | Trial primary completion date: Feb 2023 ➔ Feb 2024

Enrollment open • Trial primary completion date • Cardiovascular • Hypertension

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. (clinicaltrials.gov) - P2 | N=170 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P2 trial • Cardiovascular • Hypertension

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced Ejection Fraction (HFrEF) (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial primary completion date: May 2022 ➔ Jun 2023

Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced Ejection Fraction (HFrEF) (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting | N=18 ➔ 27 | Trial completion date: Oct 2022 ➔ Apr 2023 | Trial primary completion date: Oct 2022 ➔ May 2022

Enrollment change • Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced Ejection Fraction (HFrEF) (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New P1 trial • Cardiovascular • Congestive Heart Failure • Heart Failure